Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...
the company unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance and technology leadership in the rapidly growing field of spatial biology. 10x ...
Cloud Analysis for Large Studies will help researchers looking to automate data processing programmatically while taking advantage of 10x Cloud's high-performance infrastructure. These capabilities ...
In 2024, 10x Genomics launched its groundbreaking Visium HD product, increasing the resolution of the Visium platform by over three orders of magnitude. Now compatible with FFPE, Fresh Frozen and ...
10x Cloud Analysis for Large Studies; Visium HD 3′ for high resolution, species-agnostic spatial profiling; Visium HD Cell Segmentation for morphology-guided spatial transcriptomics; Xenium RNA ...
In addition, the company unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance and technology leadership in the rapidly growing field of spatial biology ...
10x Genomics, Inc., a life science technology ... and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results